Concepedia

Elizabeth D. Lightbody

ED

13

Publications

660

Citations

12

H-Index

2018

Active since

Affiliations

Dana-Farber Cancer Institute(Current)

Harvard University

Broad Institute

Massachusetts General Hospital

Queen's University

Elizabeth D. Lightbody is an author at Dana-Farber Cancer Institute specializing in medicine, hematology, and clinical trials.

ORCID

Top concepts

Publications per year

2018–2025

13

Publications

13

A LATS biosensor screen identifies VEGFR as a regulator of the Hippo pathway in angiogenesis

Taha Azad, Helena J. Janse van Rensburg, Elizabeth D. Lightbody et al. · Nature Communications · 2018 · 162 citations · Full text

Novel prognostic and predictive microRNA targets for triple‐negative breast cancer

Gulisa Turashvili, Elizabeth D. Lightbody, Kathrin Tyryshkin et al. · The FASEB Journal · 2018 · 84 citations

Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study

Annie Cowan, Federico Ferrari, Samuel S. Freeman et al. · The Lancet Haematology · 2023 · 72 citations · Full text

PI3K Positively Regulates YAP and TAZ in Mammary Tumorigenesis Through Multiple Signaling Pathways

Yulei Zhao, Tess Montminy, Taha Azad et al. · Molecular Cancer Research · 2018 · 67 citations

Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration

Kenneth C. Anderson, Daniel Auclair, Stacey J. Adam et al. · Clinical Cancer Research · 2021 · 62 citations · Full text

, , +18

Rows per page

1–5 of 13